( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Oncology - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets's offering. The report outlays comprehensive insights of present clinical development scenario and growth prospects across the Oncology market. A detailed picture of the Oncology pipeline landscape is provided, which includes the disease overview and Oncology treatment guidelines.
The assessment part of the report embraces in-depth Oncology commercial assessment and clinical assessment of the Oncology pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Oncology collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details. The report provides insights into: Key Questions Answered Key Topics Covered 1.
Report Introduction 2. Oncology 3. Oncology Current Treatment Patterns 4.
Oncology - Analytical Perspective 5. Therapeutic Assessment 6. Oncology Late Stage Products (Phase-III) 7.
Oncology Mid Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10.
Inactive Products 11. Dormant Products 12. Oncology Discontinued Products 13.
Oncology Product Profiles 14. Oncology Key Co.
